Haw Par Corporation Limited (HAWPF)
USD 10.0
(19.47%)
USD 10.0
(19.47%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 27.84 Million SGD | -4.64% |
| 2022 | 29.2 Million SGD | 3732.02% |
| 2021 | 762 Thousand SGD | -14.57% |
| 2020 | 892 Thousand SGD | -5.11% |
| 2019 | 940 Thousand SGD | -95.96% |
| 2018 | 23.25 Million SGD | -48.39% |
| 2017 | 45.04 Million SGD | -1.64% |
| 2016 | 45.79 Million SGD | 0.0% |
| 2015 | - SGD | 0.0% |
| 2014 | - SGD | 0.0% |
| 2013 | - SGD | 0.0% |
| 2012 | - SGD | 0.0% |
| 2011 | - SGD | 0.0% |
| 2010 | - SGD | 0.0% |
| 2009 | - SGD | 0.0% |
| 2008 | - SGD | 100.0% |
| 2007 | -67.65 Million SGD | 0.0% |
| 2006 | - SGD | 0.0% |
| 2005 | - SGD | 0.0% |
| 2004 | - SGD | -100.0% |
| 2003 | 33 Million SGD | 0.0% |
| 2002 | - SGD | 0.0% |
| 2001 | - SGD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | - SGD | 0.0% |
| 2024 Q1 | - SGD | 0.0% |
| 2023 FY | 27.84 Million SGD | -4.64% |
| 2023 Q2 | 28.01 Million SGD | 0.0% |
| 2023 Q3 | - SGD | -100.0% |
| 2023 Q1 | - SGD | -100.0% |
| 2023 Q4 | 27.84 Million SGD | 0.0% |
| 2022 Q1 | - SGD | -100.0% |
| 2022 Q4 | 29.2 Million SGD | 0.0% |
| 2022 FY | 29.2 Million SGD | 3732.02% |
| 2022 Q3 | - SGD | 0.0% |
| 2022 Q2 | - SGD | 0.0% |
| 2021 Q3 | - SGD | 0.0% |
| 2021 FY | 762 Thousand SGD | -14.57% |
| 2021 Q2 | - SGD | 0.0% |
| 2021 Q4 | 762 Thousand SGD | 0.0% |
| 2021 Q1 | - SGD | -100.0% |
| 2020 Q4 | 892 Thousand SGD | 0.0% |
| 2020 FY | 892 Thousand SGD | -5.11% |
| 2020 Q2 | - SGD | 0.0% |
| 2020 Q3 | - SGD | 0.0% |
| 2020 Q1 | - SGD | -100.0% |
| 2019 Q4 | 940 Thousand SGD | -96.12% |
| 2019 Q2 | 23.81 Million SGD | 3.28% |
| 2019 Q3 | 24.19 Million SGD | 1.59% |
| 2019 Q1 | 23.06 Million SGD | -0.81% |
| 2019 FY | 940 Thousand SGD | -95.96% |
| 2018 Q2 | 23.25 Million SGD | -0.81% |
| 2018 Q3 | 23.06 Million SGD | -0.81% |
| 2018 Q4 | 23.25 Million SGD | 0.82% |
| 2018 Q1 | 23.44 Million SGD | -47.97% |
| 2018 FY | 23.25 Million SGD | -48.39% |
| 2017 FY | 45.04 Million SGD | -1.64% |
| 2017 Q4 | 45.04 Million SGD | 0.0% |
| 2017 Q3 | - SGD | 0.0% |
| 2017 Q2 | - SGD | 0.0% |
| 2017 Q1 | - SGD | -100.0% |
| 2016 Q1 | - SGD | 0.0% |
| 2016 Q2 | - SGD | 0.0% |
| 2016 Q3 | - SGD | 0.0% |
| 2016 Q4 | 45.79 Million SGD | 0.0% |
| 2016 FY | 45.79 Million SGD | 0.0% |
| 2015 Q2 | - SGD | 0.0% |
| 2015 FY | - SGD | 0.0% |
| 2015 Q4 | - SGD | 0.0% |
| 2015 Q3 | - SGD | 0.0% |
| 2015 Q1 | - SGD | 0.0% |
| 2014 FY | - SGD | 0.0% |
| 2014 Q1 | - SGD | 0.0% |
| 2014 Q4 | - SGD | 0.0% |
| 2014 Q3 | - SGD | 0.0% |
| 2014 Q2 | - SGD | 0.0% |
| 2013 Q2 | - SGD | 0.0% |
| 2013 Q1 | - SGD | 0.0% |
| 2013 Q4 | - SGD | 0.0% |
| 2013 Q3 | - SGD | 0.0% |
| 2013 FY | - SGD | 0.0% |
| 2012 FY | - SGD | 0.0% |
| 2012 Q1 | - SGD | 0.0% |
| 2012 Q2 | - SGD | 0.0% |
| 2012 Q3 | - SGD | 0.0% |
| 2012 Q4 | - SGD | 0.0% |
| 2011 Q3 | - SGD | 0.0% |
| 2011 Q1 | - SGD | 0.0% |
| 2011 Q2 | - SGD | 0.0% |
| 2011 Q4 | - SGD | 0.0% |
| 2011 FY | - SGD | 0.0% |
| 2010 Q1 | - SGD | 0.0% |
| 2010 Q3 | - SGD | 0.0% |
| 2010 Q2 | - SGD | 0.0% |
| 2010 FY | - SGD | 0.0% |
| 2010 Q4 | - SGD | 0.0% |
| 2009 FY | - SGD | 0.0% |
| 2009 Q4 | - SGD | 0.0% |
| 2008 FY | - SGD | 100.0% |
| 2007 FY | -67.65 Million SGD | 0.0% |
| 2006 FY | - SGD | 0.0% |
| 2005 FY | - SGD | 0.0% |
| 2004 FY | - SGD | -100.0% |
| 2003 FY | 33 Million SGD | 0.0% |
| 2002 FY | - SGD | 0.0% |
| 2002 Q4 | - SGD | 0.0% |
| 2002 Q2 | - SGD | 0.0% |
| 2001 FY | - SGD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| AstraZeneca PLC | 22.33 Billion USD | 99.875% |
| Bristol-Myers Squibb Company PFD CONV 2 | 38.18 Billion USD | 99.927% |
| CSPC Pharmaceutical Group Limited | 107.05 Million USD | 73.99% |
| Clarus Therapeutics Holdings, Inc. | - USD | -Infinity% |
| Novartis AG | 20.03 Billion USD | 99.861% |
| PT Kalbe Farma Tbk. | 19.39 Million USD | -43.596% |